{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T07:13:49Z","timestamp":1764486829756,"version":"3.46.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lupus podocytopathy (LP) is an increasingly recognised and histopathologically distinct entity within the spectrum of lupus nephritis (LN). It is defined by diffuse podocyte foot process effacement in the absence of subendothelial or subepithelial immune complex deposition and often mimics minimal change disease or focal segmental glomerulosclerosis. LP is typically observed at the onset of systemic lupus erythematosus (SLE) or in patients with known LN. We report a rare case of LP in a 28-year-old Japanese woman with a 12-year history of SLE and no prior renal involvement. She presented with fever, malar rash, arthralgia, and progressive bilateral lower extremity oedema. Laboratory studies revealed marked hypoalbuminemia (1.5\u00a0g\/dl), nephrotic-range proteinuria (15\u00a0g\/gCr), elevated anti-dsDNA antibody titers (&amp;gt;400\u00a0IU\/ml), and hypocomplementemia. Renal biopsy revealed ISN\/RPS 2018 class II LN, with mild mesangial hypercellularity and mesangial deposition of IgG, C3, and C1q, without subendothelial or subepithelial immune complexes. Electron microscopy confirmed extensive foot process effacement, establishing the diagnosis of LP. The coexistence of class II LN and LP accounted for the acute onset of nephrotic syndrome in the absence of proliferative changes. The patient was treated with methylprednisolone pulse therapy, high-dose corticosteroids, and intravenous cyclophosphamide, followed by oral cyclosporine. This regimen resulted in prompt clinical and immunological improvement, including near-complete resolution of proteinuria. She remained in remission throughout a 6-month follow-up. This case emphasises the need to consider LP in SLE patients with nephrotic syndrome, even in the absence of prior renal complications during long-term follow-up.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf072","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:28:48Z","timestamp":1762777728000},"source":"Crossref","is-referenced-by-count":0,"title":["Lupus podocytopathy as a first renal manifestation in long-standing systemic lupus erythematosus: a case report"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0287-3660","authenticated-orcid":false,"given":"Tasuku","family":"Togashi","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]},{"name":"Department of Rheumatology, Sumitomo Hospital , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1718-0752","authenticated-orcid":false,"given":"Yuhei","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]},{"name":"Department of Rheumatology, Takarazuka City Hospital , Takarazuka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0033-1757","authenticated-orcid":false,"given":"Masao","family":"Katsushima","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-5816","authenticated-orcid":false,"given":"Kazuo","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-5296","authenticated-orcid":false,"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Nakatani","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Kohashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2025113002114247200_ref1","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet."},{"key":"2025113002114247200_ref2","doi-asserted-by":"crossref","first-page":"e000389","DOI":"10.1136\/lupus-2020-000389","article-title":"Prediction of prognosis and renal outcome in lupus nephritis","volume":"7","author":"Parodis","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025113002114247200_ref3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025113002114247200_ref4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MAJ.0b013e3181907b3d","article-title":"Lupus nephritis","volume":"337","author":"Singh","year":"2009","journal-title":"Am J Med Sci"},{"key":"2025113002114247200_ref5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.autrev.2011.04.032","article-title":"Epidemiology and management of refractory lupus nephritis","volume":"10","author":"Pons-Estel","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2025113002114247200_ref6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"2025113002114247200_ref7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"2025113002114247200_ref8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40620-017-0463-1","article-title":"Lupus podocytopathy: a distinct entity of lupus nephritis","volume":"31","author":"Chen","year":"2018","journal-title":"J Nephrol"},{"key":"2025113002114247200_ref9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.ackd.2019.08.011","article-title":"Lupus podocytopathy: an overview","volume":"26","author":"Oliva-Damaso","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025113002114247200_ref10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/rheumatology\/ket491","article-title":"Podocyte involvement in lupus nephritis based on the 2003 ISN\/RPS system: a large cohort study from a single Centre","volume":"53","author":"Wang","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2025113002114247200_ref11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2004050350","article-title":"Glomerular podocytopathy in patients with systemic lupus erythematosus","volume":"16","author":"Kraft","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025113002114247200_ref12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2215\/CJN.06720615","article-title":"Clinical-morphological features and outcomes of lupus podocytopathy","volume":"11","author":"Hu","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025113002114247200_ref13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/clinpract11040089","article-title":"Delayed onset minimal change disease as a manifestation of lupus podocytopathy","volume":"11","author":"Aly","year":"2021","journal-title":"Clin Pract"},{"key":"2025113002114247200_ref14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"2024 Clinical practice guideline for the management of lupus nephritis","volume":"105","author":"KDIGO","year":"2024","journal-title":"Kidney Int"},{"key":"2025113002114247200_ref15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/0961203315578766","article-title":"Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study","volume":"24","author":"Hu","year":"2015","journal-title":"Lupus."},{"key":"2025113002114247200_ref16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine a","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"2025113002114247200_ref17","doi-asserted-by":"crossref","first-page":"e0132724","DOI":"10.1371\/journal.pone.0132724","article-title":"Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis","volume":"10","author":"Liao","year":"2015","journal-title":"PLoS One"},{"key":"2025113002114247200_ref18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ki.2012.412","article-title":"Therapy of relapsing minimal-change disease in adults: a new approach?","volume":"83","author":"Glassock","year":"2013","journal-title":"Kidney Int"},{"key":"2025113002114247200_ref19","doi-asserted-by":"crossref","first-page":"2050313x17695997","DOI":"10.1177\/2050313X17695997","article-title":"Recurrent podocytopathy in a patient with systemic lupus erythematosus","volume":"5","author":"Paramalingam","year":"2017","journal-title":"SAGE Open Med Case Rep"},{"key":"2025113002114247200_ref20","first-page":"1","article-title":"Is it coincidence or consequence for a case with antiphospholipid antibody syndrome overlapping SLE to develop an immune complex nephropathy followed by a nonimmune complex podocytopathy?","volume":"2018","author":"Yoo","year":"2018","journal-title":"Case Rep Nephrol"},{"key":"2025113002114247200_ref21","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227860","article-title":"Haemophagocytic lymphohistiocytosis with collapsing lupus podocytopathy as an unusual manifestation of systemic lupus erythematosus with APOL1 double-risk alleles","volume":"12","author":"Chokshi","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2025113002114247200_ref22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.21037\/apm.2019.09.02","article-title":"Lupus podocytopathy complicated with multiple organ injuries in a patient with severe lupus","volume":"8","author":"Wu","year":"2019","journal-title":"Ann Palliat Med"},{"key":"2025113002114247200_ref23","first-page":"1","article-title":"The various forms of nephrotic syndrome in a patient with systemic lupus erythematosus","volume":"2020","author":"Lionaki","year":"2020","journal-title":"Case Rep Nephrol"},{"key":"2025113002114247200_ref24","doi-asserted-by":"crossref","first-page":"e27077","DOI":"10.1097\/MD.0000000000027077","article-title":"Lupus podocytopathy superimposed on diabetic glomerulosclerosis: a case report","volume":"100","author":"Liu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2025113002114247200_ref25","first-page":"57","article-title":"Lupus podocytopathy: a rare cause of nephrotic syndrome in patients with systemic lupus erythematosus","volume":"13","author":"Khan","year":"2023","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"2025113002114247200_ref26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2025113002114247200_ref27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025113002114247200_ref28","doi-asserted-by":"crossref","first-page":"e000910","DOI":"10.1136\/lupus-2023-000910","article-title":"Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial","volume":"10","author":"Jayne","year":"2023","journal-title":"Lupus Sci Med"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf072\/65269222\/rxaf072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf072\/65269222\/rxaf072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf072\/65269222\/rxaf072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T07:11:51Z","timestamp":1764486711000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf072\/8320498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf072","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf072"}}